NCT00203190终止4 期
A Single-Center, Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Topiramate in the Treatment of Subjects With Episodic or Chronic Cluster Headache.
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- Change in the average daily frequency of moderate or severe attacks between baseline period to the period of day 14 to 56.
研究概览
简要总结
Topiramate is a medication that has been approved by the Food and Drug Administration (FDA) for the treatment of patients with seizures. The trade name for this drug is Topamax®. Topiramate has not been approved by the FDA for the treatment of cluster headache and is experimental for the purposes of this research study. If a subject participates in this study, he/she will increase his/her dose of topiramate rapidly in the first few weeks to try to stop the cluster attacks and then will continue on a maintenance dose of topiramate in order to determine if it can prevent attacks from occurring during that cluster period. We believe that this will lead not only to a faster but a more complete remission of the cluster period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects between the ages of 18 and 65 with a diagnosis of cluster headache (episodic or chronic) as defined by the International Classification of Headache Disorders (2nd edition)
- •Subjects must have a lifetime prevalence of at least 2 prior cluster cycles.
- •Subjects must experience one or more attacks/ day during baseline period
- •Subjects must have a typical cluster period lasting at least 8 weeks. Subjects must present in active cluster period and the expected remaining duration of the cluster cycle must be at least 8 weeks from Baseline visit.
- •Subjects with other headache types are eligible provided the subject is able to differentiate these headaches from cluster headaches.
- •Subject is using or agrees to use for the duration of participation a medically acceptable form of contraception (as determined by investigator), if female of child-bearing potential
- •Subject has negative urine pregnancy test prior to study entry, if female of child-bearing potential
- •Subject is able to understand and comply with all study requirements
- •Subject provides written informed consent prior to any screening procedures being conducted
排除标准
- •Women who are pregnant or lactating
- •Subjects who, in the investigators opinion, have a history or have evidence of a medical or psychiatric condition that would expose them to an increased risk of a significant adverse event or would interfere with the assessments of efficacy and tolerability during this trial
- •Subjects who require a change in medication or existing regimen of medication for the prophylaxis of cluster in the 4 weeks prior to Baseline visit and for the duration of the trial
- •Subjects who have cluster headaches that typically exceed 4 hours
- •Subjects who have used the following medications/ treatments from four weeks prior to Baseline visit: corticosteroids and nerve blocks.
- •Subjects using any drug which might interact adversely with, or interfere with the action of, the study medication (e.g., carbonic anhydrase inhibitors)
- •Subjects who have failed an adequate trial of topiramate for cluster headaches due to lack of efficacy or adverse events, as determined by the investigator
- •Subjects with a history of nephrolithiasis.
- •Subjects who are allergic to or have shown hypersensitivity topiramate or agents similar to topiramate
- •Subjects who abuse opioids as determined by investigator
- •Subjects with a history of significant drug or alcohol abuse within the past year
- •Subjects who have participated in an investigational drug trial in the 30 days prior to the screening visit
结局指标
主要结局
Change in the average daily frequency of moderate or severe attacks between baseline period to the period of day 14 to 56.
次要结局
- Change in the average daily frequency of any attacks from the baseline period through the entire treatment period.
- Change in the average daily duration of any attacks from the baseline period through the entire treatment period.
- Change in the average daily attack severity from baseline period through the entire treatment period.
- Change in the average daily frequency of any attacks from the baseline period to each week during the treatment period.
- Change in the average daily duration of any attacks from the baseline period to each week during the treatment period.
- Change in the average daily attack severity from the baseline period to each week during the treatment period.
- Time to the first week from the baseline period with a 50% reduction in average daily frequency of moderate or severe attacks.
- Change in use of acute and rescue medications from the baseline period through the entire treatment period.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive DisorderObsessive-Compulsive DisorderNCT00187928University of Florida96
已完成
4 期
Topiramate in the Treatment of Posttraumatic Stress Disorder in CiviliansPost-Traumatic Stress DisorderNCT00208130Creighton University60
已完成
3 期
A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)Acute Myelogenous LeukemiaNCT00317642Genzyme, a Sanofi Company326
终止
4 期
Topiramate: Long-Term Maintenance of Weight Loss Induced by Low-Calorie Diet in Obese SubjectsObesityNCT02040311University of Copenhagen701
已完成
3 期
A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer PatientsNon-Small Cell Lung CancerNCT00085826Astellas Pharma Inc600